Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals held its Q1 2026 earnings call on April 30, 2026, to discuss financial results and business updates. Company executives, including CEO Michael Metzger and CFO Keith Goldan, provided insights into operations, research and development, and commercial strategy. Analysts from major financial institutions participated in the question-and-answer session following the presentation.
- ▪Syndax Pharmaceuticals, Inc. (SNDX) conducted its Q1 2026 earnings call on April 30, 2026, at 4:30 PM EDT.
- ▪Company participants included Michael Metzger (CEO), Keith Goldan (CFO), Steven Closter (Chief Commercial Officer), and Nicholas Botwood (Head of R&D and Chief Medical Officer).
- ▪Sharon Klahre, Vice President of Investor Relations & Communications, also participated in the call.
- ▪Analysts from JPMorgan, Goldman Sachs, TD Cowen, Guggenheim Securities, B. Riley Securities, Barclays, UBS, Citigroup, BofA Securities, Mizuho Securities, and H.C. Wainwright asked questions during the session.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4897195-syndax-pharmaceuticals-inc-sndx-q1-2026-earnings-call-transcript"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
